Form 4: Beta Bionics CMO Reports Equity Transactions

Beta Bionics' Chief Medical Officer, Steven Jon Russell, reported the acquisition of restricted stock units and stock options, alongside a sale of shares to cover tax obligations.

Summary

• Steven Jon Russell, Chief Medical Officer of Beta Bionics, Inc. (BBNX), reported transactions involving the company's common stock and employee stock options.
• On February 27, 2026, Mr. Russell acquired 109,105 shares of Common Stock as a restricted stock unit (RSU) award under the Issuer's 2025 Equity Incentive Plan, with a transaction price of $0.
• On February 27, 2026, Mr. Russell also acquired 58,749 employee stock options with an exercise price of $12.63. These options will vest in 36 equal monthly installments starting March 1, 2026, and expire on February 26, 2036.
• On March 2, 2026, Mr. Russell disposed of 1,026 shares of Common Stock at a weighted average sale price of $12.3616. This sale was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following these reported transactions, Mr. Russell beneficially owns 179,096 shares of Common Stock and 58,749 employee stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting routine executive compensation and tax-related transactions that align management incentives without indicating significant operational changes.

Positives

• The grant of 109,105 restricted stock units and 58,749 employee stock options aligns the Chief Medical Officer's long-term interests with those of shareholders, incentivizing performance and retention.
• The acquisition of equity awards is a standard component of executive compensation, indicating continued commitment to the company.

Negatives

• A disposition of 1,026 shares, although for tax withholding purposes, slightly reduces the Chief Medical Officer's direct beneficial ownership of common stock.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not typically provide broader industry insights. These transactions reflect routine executive compensation practices within publicly traded companies.

Stakeholder Impact

• Shareholders: The grant of equity awards aligns the Chief Medical Officer's interests with shareholders, while the tax-related sale is a minor, routine event that does not significantly impact the company's fundamentals or share structure.

Next Steps

• Vesting of 58,749 employee stock options in 36 equal monthly installments starting March 1, 2026.

Key Dates

Recommendation

This Form 4 details routine executive compensation and tax-related share sales, which are standard occurrences and do not provide new fundamental information to warrant a change in investment recommendation. The transactions reflect ongoing alignment of management incentives with shareholder value rather than a shift in company outlook or performance.

Keywords

Beta Bionics, BBNX, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Stock Options, Equity Incentive Plan, Chief Medical Officer